Skip to main content

Peer Review reports

From: Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Original Submission
11 Dec 2019 Submitted Original manuscript
23 Jan 2020 Author responded Author comments - Ashley Hopkins
9 Jan 2020 Reviewed Reviewer Report - Lucie Heinzerling
12 Jan 2020 Reviewed Reviewer Report - Bastian Schilling
16 Jan 2020 Reviewed Reviewer Report - Katharina Kähler
Resubmission - Version 2
23 Jan 2020 Submitted Manuscript version 2
13 Feb 2020 Author responded Author comments - Ashley Hopkins
24 Jan 2020 Reviewed Reviewer Report - Bastian Schilling
Resubmission - Version 3
13 Feb 2020 Submitted Manuscript version 3
16 Feb 2020 Author responded Author comments - Ashley Hopkins
Resubmission - Version 4
16 Feb 2020 Submitted Manuscript version 4
Publishing
20 Feb 2020 Editorially accepted
27 Feb 2020 Article published 10.1186/s12885-020-6659-0

You can find further information about peer review here.

Back to article page